The Cochrane Database of Systematic Reviews (CDSR) achieved a 2022 Impact Factor of 8.4. This means that a Review published during 2020 and 2021 was cited, on average, 8.4 times in 2022 (source: Wiley, Cochrane Library 2022 Impact Report).

The most cited reviews in 2022 were:

1. Body weight management in overweight and obese breast cancer survivors
2. PARP inhibitors for locally advanced or metastatic breast cancer
3. Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast reconstruction
4. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
5. Platinum-containing regimens for triple-negative metastatic breast cancer
6. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer
7. Perioperative systemic nonsteriodal anti-inflammatory drugs (NSAIDs) in women undergoing breast surgery
8. Oncoplastic breast-conserving surgery for women with primary breast cancer
9. Partial breast irradiation versus whole breast radiotherapy for early breast cancer
10. Paravertebral anaesthesia with or without sedation versus general anaesthesia for women undergoing breast cancer surgery.